2 unknown. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Unknown 2 |
Follow Atsushi Kawakami: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate filgotinib 200mg/day, subcutaneous tocilizumab 162mg/biweekly - Rheumatoid Arthritis, JAK Inhibitor | Phase 3 | Unknown | Atsushi Kawakami | 400 | 2021-03-03 | 2021-11-01 |
| Discontinuation of Methotrexate in Rheumatoid Arthritis Patients Achieving Clinical Remission by Treatment With Upadacitinib Plus Methotrexate upadacitinib 15mg/day - Rheumatoid Arthritis, JAK Inhibitor | Phase 3 | Unknown | Atsushi Kawakami | 155 | 2021-01-12 | 2021-12-08 |
GLPG0634 (1) · upadacitinib (1)
Japan (2)